JP2022527638A5 - - Google Patents

Info

Publication number
JP2022527638A5
JP2022527638A5 JP2021560323A JP2021560323A JP2022527638A5 JP 2022527638 A5 JP2022527638 A5 JP 2022527638A5 JP 2021560323 A JP2021560323 A JP 2021560323A JP 2021560323 A JP2021560323 A JP 2021560323A JP 2022527638 A5 JP2022527638 A5 JP 2022527638A5
Authority
JP
Japan
Prior art keywords
composition according
composition
salt
phospholipid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527638A (ja
JP7583741B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025246 external-priority patent/WO2020205530A1/en
Publication of JP2022527638A publication Critical patent/JP2022527638A/ja
Publication of JP2022527638A5 publication Critical patent/JP2022527638A5/ja
Application granted granted Critical
Publication of JP7583741B2 publication Critical patent/JP7583741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560323A 2019-03-29 2020-03-27 リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法 Active JP7583741B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
US62/826,874 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (3)

Publication Number Publication Date
JP2022527638A JP2022527638A (ja) 2022-06-02
JP2022527638A5 true JP2022527638A5 (cg-RX-API-DMAC7.html) 2023-04-03
JP7583741B2 JP7583741B2 (ja) 2024-11-14

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560323A Active JP7583741B2 (ja) 2019-03-29 2020-03-27 リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法

Country Status (19)

Country Link
US (1) US12691131B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946365A4 (cg-RX-API-DMAC7.html)
JP (1) JP7583741B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210143906A (cg-RX-API-DMAC7.html)
CN (1) CN113873998A (cg-RX-API-DMAC7.html)
AR (1) AR119705A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020252005B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134828A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002512A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014274A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192663A1 (cg-RX-API-DMAC7.html)
IL (1) IL286713B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021011876A (cg-RX-API-DMAC7.html)
PE (1) PE20212366A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552428A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110623PA (cg-RX-API-DMAC7.html)
TW (1) TWI906214B (cg-RX-API-DMAC7.html)
WO (1) WO2020205530A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
US20250248939A1 (en) * 2022-04-18 2025-08-07 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO2000051565A1 (en) 1999-03-02 2000-09-08 The Liposome Company, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
US7011845B2 (en) 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
HUP0303616A3 (en) 2001-03-26 2006-07-28 Alza Corp Mountain View Liposome composition for improved intracellular delivery of a therapeutic agent
CA2471960A1 (en) 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation
EP1478341A4 (en) 2002-01-09 2009-05-20 Transave Inc EFFICIENT ENCAPSULATION OF NUCLEIC ACIDS IN MEDIUM SIZE LIPOSOMES
WO2004103510A2 (en) 2003-05-14 2004-12-02 The Regents Of The University Of Colorado Methods and apparatus using electrostatic atomization to form liquid vesicles
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
JP2008518925A (ja) 2004-10-29 2008-06-05 ネオファーム、インコーポレイティッド リポソーム製剤の製造プロセス
FR2897779B1 (fr) 2006-02-24 2009-04-17 Orphan Europ Sarl Manossyl-1 phosphates, procede de preparation et utilisation en therapeutique, notamment vis-a-vis dy syndrome cdg-la
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
CA2761916A1 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
WO2010138550A1 (en) 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20110257233A1 (en) 2010-03-19 2011-10-20 Sanford-Burnham Medical Research Institute Benzoisothiazolones as inhibitors of phosphomannose isomerase
EP2598120B1 (en) 2010-07-31 2018-09-05 The Scripps Research Institute Compositions and methods for inducing immune tolerance
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
WO2014063757A1 (en) 2012-10-26 2014-05-01 Universiteit Leiden Delivery methods
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
ES3026657T3 (en) 2013-09-16 2025-06-11 Glycomine Inc Pharmaceutical preparation of carbohydrates for therapeutic use
US20150132369A1 (en) 2013-11-09 2015-05-14 Exir Nano Sina Company Nanoliposomal cyclosorin formulations for immunosuppresion and methods for the production thereof
CN107207614B (zh) 2014-10-09 2022-01-11 利普泰克有限公司 嵌合蛋白
US20170165374A1 (en) 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections
MX2021011876A (es) 2019-03-29 2022-01-04 Glycomine Inc Formulaciones liposomicas y metodos de uso y preparacion de las mismas.

Similar Documents

Publication Publication Date Title
CA2772965C (en) Medical use of spla2 hydrolysable liposomes
US20110237510A1 (en) Stabilized glucagon solutions
JP2014519493A (ja) ポリマー共役脂質を含むリポソームおよび関連用途
US8912162B2 (en) Parenteral formulations of elacytarabine derivatives
JP5735724B2 (ja) 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法
JP2008534525A (ja) リン脂質のポリエチレングリコール誘導体に包み込まれたアンスラサイクリン系抗腫瘍抗生物質のナノミセル製剤
KR100520738B1 (ko) 간염 치료제
US8241663B2 (en) Liposome preparation
JP2022527638A (ja) リポソーム製剤、ならびにリポソーム製剤を使用および調製する方法
JPWO2005021012A1 (ja) ゲムシタビン封入薬剤担体
JP2009530318A (ja) 加水分解時に分子内環化反応を行うホスホリパーゼa2分解性脂質を含む脂質ベース薬剤送達系
TW202143978A (zh) 格列本脲脂質體組合物及其製備方法
JP2025506429A5 (cg-RX-API-DMAC7.html)
EP1594488B1 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
US20240261311A1 (en) Methods of treating or preventing allergies and chronic nasal congestion
TH2101006052A (th) สูตรผสมไลโปโซม, และวิธีการใช้และการเตรียมของสิ่งดังกล่าว
Sandal et al. Liposomal drug delivery: recent developments and challenges
JPH04356421A (ja) プロスタグランジン類含有脂肪小体組成物
EP4667475A1 (en) Ph-responsive phospholipid
CN101014322A (zh) 盐水中富含固醇的添加两性霉素的混合层状脂质体及其制备方法
US20250228902A1 (en) Combination drug for treating malignant tumor
JPH0574573B2 (cg-RX-API-DMAC7.html)
JP2000302685A (ja) 抗腫瘍薬含有リポソーム製剤
JPH11199488A (ja) 抗腫瘍薬のリポソーム化製剤
CN104546719A (zh) 一种载Z-GP-Dox的混合胶束制剂及其制备方法